(Q33378637)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1827346%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

title

Danazol treatment of myelodysplastic syndromes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1827346%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

1

E A Stadtmauer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1827346%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

author name string

P. A. Cassileth

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1827346

3 December 2022

M. Edelstein

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1827346

3 December 2022

J. Abrahm

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1827346

3 December 2022

A. D. Schreiber

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1827346

3 December 2022

P. C. Nowell

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1827346

3 December 2022

D. B. Cines

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1827346

3 December 2022

language of work or name

English

0 references

publication date

1 April 1991

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1827346%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

19 September 2019

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2141.1991.tb08617.x

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.1991.tb08617.x/fullpdf

3 December 2022

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

British Journal of Haematology

3 December 2022

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1827346%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

volume

77

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1827346%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1827346%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

page(s)

502-508

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1827346%20AND%20SRC:MED&resulttype=core&format=json

Danazol therapy for autoimmune hemolytic anemia

19 September 2019

cites work

4

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Danazol for the treatment of idiopathic thrombocytopenic purpura

3 December 2022

5

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Lymphocyte abnormalities in preleukemia — I. Decreased NK activity, anomalous immunoregulatory cell subsets and deficient EBV receptors

3 December 2022

6

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Allogeneic Marrow Transplantation in the Treatment of Preleukemia

3 December 2022

7

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Mechanisms of glucocorticosteroid activity in patients with the preleukemic syndrome (hemopoietic dysplasia)

3 December 2022

9

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Proposals for the classification of the myelodysplastic syndromes

3 December 2022

10

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Management of myelodysplastic syndromes.

3 December 2022

12

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Modulation of the human monocyte binding site for monomeric immunoglobulin G by activated Hageman factor

3 December 2022

13

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Danazol therapy in myelodysplasia

3 December 2022

14

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Immune thrombocytopenic purpura and pregnancy

3 December 2022

15

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Platelet membrane glycoprotein abnormalities in patients with myeloproliferative disorders and secondary thrombocytosis

3 December 2022

16

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Immunologic indices in myelodysplastic syndromes

3 December 2022

17

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases

3 December 2022

18

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside.

3 December 2022

21

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

3 December 2022

Human preleukemia

23

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Management of myelodysplastic syndromes

3 December 2022

24

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders

3 December 2022

25

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Platelet Fc receptor. Increased expression in myeloproliferative disease

3 December 2022

26

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies

3 December 2022

27

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

13-cis retinoic acid treatment for myelodysplastic syndromes

3 December 2022

28

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Effect of danazol in immune thrombocytopenic purpura

3 December 2022

30

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Erythrocyte autoantibodies, autoimmune haemolysis, and myelodysplastic syndromes

3 December 2022

31

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Hematologic and cytogenetic remission of 5q-refractory anemia after syngeneic bone marrow transplantation

3 December 2022

33

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia

3 December 2022

37

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

Response of preleukemic syndromes to continuous infusion of low-dose cytarabine

3 December 2022

38

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1991.TB08617.X

3 December 2022

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1827346%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

1 reference